Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 2/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9375869 | 0.85 | MAPK14 (0.49) | MAPK14CA9PGR | |
| SCHEMBL21904332 | 0.81 | MAPK14 (0.52) | MAPK14CA9BACE1TNKSTNKS2 | |
| SCHEMBL30898665 | 0.81 | MAPK14 (0.44) | MAPK14BACE1MEN1GAAKMT2A | |
| SCHEMBL12845648 | 0.81 | MAPK14 (0.44) | MAPK14BACE1TNKSTNKS2PGR | |
| SCHEMBL1232157 | 0.81 | MAPK14 (0.44) | MAPK14BACE1MEN1GAAKMT2A | |
| SCHEMBL1233579 | 0.77 | BACE1 (0.58) | BACE1TNKSTNKS2KDM4EMEN1 | |
| SCHEMBL22271500 | 0.75 | PGR (0.53) | CA9PGR | |
| SCHEMBL21904060 | 0.74 | OPRL1 (0.46) | MEN1GAAKMT2AOPRM1OPRK1 | |
| SCHEMBL30468493 | 0.74 | OPRL1 (0.46) | MEN1GAAKMT2AOPRM1OPRK1 | |
| SCHEMBL20269069 | 0.72 | PGR (0.55) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110769821-B | Spiro indolines as IL-17 modulators | UCB生物制药有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-3638227-B1 | SPIROCYCLIC INDOLINES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2022-08-10 | — | — | EP | disclosed |
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| US-20200138797-A1 | Spirocyclic Indolines as IL-17 Modulators | UCB Biopharma SRL (BE) | 2020-05-07 | — | — | US | disclosed |
| CN-110769821-A | Spirocyclic indolines as IL-17 modulators | UCB生物制药私人有限公司 | 2020-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | IL17A, IL2, IL18 | MAPK14 308/4885CA9 4735/4885BACE1 3728/4885 |
| US-20200138797-A1 | Spirocyclic Indolines as IL-17 Modulators | IL17A, IL2, IL18 | MAPK14 308/4885CA9 4735/4885BACE1 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.